Literature DB >> 31055710

Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE).

Mariko M Nakano1, Akira Yamamoto2, Norifumi Nishida3, Masao Hamuro1, Shinichi Hamamoto1, Atsushi Jogo1, Etsuji Sohgawa1, Ken Kageyama1, Tetsuya Minami4, Yukio Miki1.   

Abstract

PURPOSE: To identify the risk factors for local recurrence in hepatocellular carcinoma (HCC) patients treated with transcatheter arterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE).
MATERIALS AND METHODS: In this retrospective study, 35 patients (27 males, 8 females; median age 73 years) with 116 tumors (median size 14 mm) treated with DEB-TACE from May 2014 to September 2018 were evaluated. Age, sex, etiology, Child-Pugh class, alpha-fetoprotein, des-gamma-carboxyprothrombin, previous conventional TACE, tumor location, tumor size, tumor number, contact with the liver surface, level of embolization, corona enhancement on CT during hepatic arteriography, vascular lakes, additional embolization with gelatin sponge particles, and supplying vessels on digital subtraction angiography (DSA) after embolization were analyzed.
RESULTS: Univariate analysis showed that advanced age, female, large tumor, contact with the liver surface, and residual supplying vessels were significant risk factors for local recurrence (p = 0.012, 0.0013, 0.0023, 0.025, and < 0.001, respectively). On multivariate logistic analysis, large tumor, contact with the liver surface, and residual supplying vessels on DSA were significant risk factors for local recurrence (p = 0.0026, 0.038, and < 0.001, respectively).
CONCLUSION: Large tumor size, contact with the liver surface, and residual supplying vessels on DSA were significant risk factors associated with local recurrence after DEB-TACE for HCC.

Entities:  

Keywords:  DEB-TACE; Drug-eluting bead; Hepatocellular carcinoma; Risk factor

Mesh:

Substances:

Year:  2019        PMID: 31055710     DOI: 10.1007/s11604-019-00840-4

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  6 in total

1.  Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial Embolization: A Retrospective Study on Patterns, Treatments, and Prognoses.

Authors:  Crisanta H Ilagan; Debra A Goldman; Mithat Gönen; Victoria G Aveson; Michelle Babicky; Vinod P Balachandran; Jeffrey A Drebin; William R Jarnagin; Alice C Wei; T Peter Kingham; Ghassan K Abou-Alfa; Karen T Brown; Michael I D'Angelica
Journal:  Ann Surg Oncol       Date:  2022-07-15       Impact factor: 4.339

2.  Drug-Eluting Beads versus Lipiodol Transarterial Chemoembolization for the Treatment of Hypovascular Hepatocellular Carcinoma: A Single-Center Retrospective Study.

Authors:  Qin Shi; Dandan Chen; Chen Zhou; Jiacheng Liu; Songjiang Huang; Chongtu Yang; Bin Xiong
Journal:  Cancer Manag Res       Date:  2020-07-06       Impact factor: 3.989

3.  Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20-40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm.

Authors:  Su Min Cho; Hee Ho Chu; Jong Woo Kim; Jin Hyung Kim; Dong Il Gwon
Journal:  Life (Basel)       Date:  2021-04-18

4.  Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma.

Authors:  Jingjun Huang; Wensou Huang; Meixiao Zhan; Yongjian Guo; Licong Liang; Mingyue Cai; Liteng Lin; Mingji He; Hui Lian; Ligong Lu; Kangshun Zhu
Journal:  J Hepatocell Carcinoma       Date:  2021-11-26

5.  Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features.

Authors:  Zhi-Wei Li; A-Hong Ren; Da-Wei Yang; Hui Xu; Jian Wei; Chun-Wang Yuan; Zhen-Chang Wang; Zheng-Han Yang
Journal:  BMC Med Imaging       Date:  2022-10-07       Impact factor: 2.795

Review 6.  Role of modern radiotherapy in managing patients with hepatocellular carcinoma.

Authors:  Liang-Cheng Chen; Hon-Yi Lin; Shih-Kai Hung; Wen-Yen Chiou; Moon-Sing Lee
Journal:  World J Gastroenterol       Date:  2021-05-28       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.